Impact of ACAs at initial diagnosis and ACAs acquired during therapy on blastic transformation. (A-B) Impact of ACAs at initial diagnosis on blastic transformation of CML by risk group. Patients who had BP at initial diagnosis were excluded in panel A but included in panel B. (C-D) Impact of ACAs acquired during therapy on blastic transformation of CML from emergence of ACAs. Patients with ACAs detected at blastic transformation were excluded in panel C but included in panel D.